If you are wondering which stocks to watch out for, here’s a quick roundup of companies making headlines – from fundraising moves and strategic deals to regulatory approvals and global partnerships. Let’s take a look at the stocks that are in focus today.
Market recap
Indian equity benchmarks ended the day on a muted note on June 2, weighed down by intraday volatility. The Sensex slipped 77.26 points or 0.09% to close at 81,373.75, while the Nifty shed 34.10 points or 0.14%, settling at 24,716.60.
Stocks to watch on June 03, 2025
Grasim Industries
Grasim Industries, the flagship of the Aditya Birla Group, is tapping the bond market. Its Finance Committee has approved the issuance of non-convertible debentures (NCDs) worth up to Rs 1,000 crore.
These unsecured, listed, and redeemable bonds priced at Rs 1,00,000 each will be placed privately in one or more tranches.
HCL Technologies
In a global partnership announcement, HCL Tech said it will work with UiPath, a global leader in agentic automation. The goal is to bring intelligent, autonomous business process automation to global clients.
“Agentic automation” refers to smart bots that don’t just follow instructions – they learn, make decisions, and adapt on their own, minimizing human intervention. This tech will be deployed across finance, HR, operations, and IT workflows, enabling large-scale transformation.
Torrent Power
Torrent Power has signed a long-term LNG supply agreement with BP Singapore, the energy arm of global oil giant BP. The deal involves supplying up to 0.41 million tonnes per annum (MTPA) of LNG from 2027 to 2036.
This LNG will be used to operate Torrent’s 2,730 MW gas-based power plants.
Biocon
Biocon has received approval from Indian regulators for its version of Liraglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes drug Victoza.
The injectable drug is used to treat Type 2 diabetes in adults and children aged 10 and above, alongside diet and exercise. Biocon Pharma, the company’s wholly owned subsidiary, also got clearance for pre-filled pens and cartridges of the product.
Glenmark Pharma
Ichnos Glenmark Innovation (IGI), a biotech joint venture between Glenmark Pharmaceuticals and Ichnos Sciences, has shared positive results from a Phase 1 global study.
The experimental treatment is aimed at relapsed or refractory multiple myeloma, a blood cancer affecting bone marrow.
UGRO Capital
Fintech-focused NBFC UGRO Capital has approved the final terms for its much-awaited rights issue. The company will raise up to Rs 400 crore by offering new shares to its existing public shareholders at Rs 162 per share.
This move follows UGRO’s earlier announcement on May 20 about raising Rs 915 crore via compulsory convertible debentures (CCDs).
MAN Industries
Mumbai-based MAN Industries, known for making pipes for oil and gas infrastructure, has announced plans to raise up to Rs 300 crore.
The company will issue 12.19 lakh convertible warrants to Man Finance (a promoter entity) and 79.26 lakh equity shares to non-promoters, all priced at Rs 328 apiece.